CytoMed Therapeutics (GDTC) Total Liabilities (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Total Liabilities of $872875.4 for Q4 2025, down 23.09% sequentially from $1.1 million in Q2 2025, and up 13.39% YoY from $769789.0 in Q4 2024.
CytoMed Therapeutics (GDTC) Total Liabilities (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Total Liabilities for 5 years, with the latest figure at $872875.4 in Q4 2025.
- Quarterly Total Liabilities rose 13.39% year-over-year to $872875.4 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $872875.4 (up 13.39% YoY) and the FY2025 annual result came in at $879762.0, up 14.77% from the prior year.
- Total Liabilities declined to $872875.4 in Q4 2025 per GDTC's latest filing, from $1.1 million in the prior quarter.
- Over five years, Total Liabilities peaked at $3.3 million in Q4 2022 and troughed at $746073.0 in Q2 2023.
- A 5-year average of $1.4 million and a median of $852971.6 in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities tumbled 75.09% in 2023, then surged 51.55% in 2025.
- Over 5 years, Total Liabilities stood at $2.6 million in 2021, then grew by 29.99% to $3.3 million in 2022, then sank by 75.09% to $833067.9 in 2023, then fell by 7.6% to $769789.0 in 2024, then gained by 13.39% to $872875.4 in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $872875.4, $1.1 million, and $769789.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 10.03 Bn |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - | 872,875.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 872,875.35 |
| Jun 30, 2025 | 1.13 Mn |
| Dec 31, 2024 | 769,789.01 |
| Jun 30, 2024 | 748,815.00 |
| Dec 31, 2023 | 833,067.92 |
| Jun 30, 2023 | 746,073.00 |
| Dec 31, 2022 | 3.34 Mn |
| Dec 31, 2021 | 2.57 Mn |